CLINICAL TRIALS PROFILE FOR XIIDRA
✉ Email this page to a colleague
All Clinical Trials for Xiidra
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03408015 ↗ | Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease | Withdrawn | Shire | Phase 4 | 2019-01-01 | Every night during sleep, there is an accumulation of white blood cells in the closed eye. The closed eye white blood cells are predominantly neutrophils, but there is a small population (3%) of T cells. The effects of these closed eye white blood cells on dry eye disease pathogenesis have yet to be fully elucidated, but preliminary evidence suggests that closed eye neutrophils may have an associated hyperactivity and increased degranulation in dry eye disease that could contribute to epithelial instability. As an anti-T cell therapy, Xiidra offers an opportunity to better understand how the closed eye white blood cells are recruited and activated. This study also seeks to verify the proposed mechanism of action. |
| NCT03408015 ↗ | Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease | Withdrawn | University of Alabama at Birmingham | Phase 4 | 2019-01-01 | Every night during sleep, there is an accumulation of white blood cells in the closed eye. The closed eye white blood cells are predominantly neutrophils, but there is a small population (3%) of T cells. The effects of these closed eye white blood cells on dry eye disease pathogenesis have yet to be fully elucidated, but preliminary evidence suggests that closed eye neutrophils may have an associated hyperactivity and increased degranulation in dry eye disease that could contribute to epithelial instability. As an anti-T cell therapy, Xiidra offers an opportunity to better understand how the closed eye white blood cells are recruited and activated. This study also seeks to verify the proposed mechanism of action. |
| NCT03431272 ↗ | Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers | Withdrawn | Shire | Phase 4 | 2018-11-01 | Discomfort with contact lens wear is the biggest reason why people stop wearing contact lenses. The investigators believe that inflammation is one of the causes of discomfort, and by blocking the inflammation using lifitegrast, the investigators may be able to relieve some of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will receive lifitegrast to use over a period of approximately 3 months. |
| NCT03431272 ↗ | Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers | Withdrawn | University of Alabama at Birmingham | Phase 4 | 2018-11-01 | Discomfort with contact lens wear is the biggest reason why people stop wearing contact lenses. The investigators believe that inflammation is one of the causes of discomfort, and by blocking the inflammation using lifitegrast, the investigators may be able to relieve some of that discomfort. This study will enroll 50 subjects with contact lens discomfort and will receive lifitegrast to use over a period of approximately 3 months. |
| NCT03952481 ↗ | Effect of Lifitegrast 5% on Tear Film Markers | Withdrawn | Novartis | Phase 4 | 2021-03-01 | The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes. |
| NCT03952481 ↗ | Effect of Lifitegrast 5% on Tear Film Markers | Withdrawn | Shire Human Genetic Therapies, Inc. | Phase 4 | 2021-03-01 | The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes. |
| NCT03952481 ↗ | Effect of Lifitegrast 5% on Tear Film Markers | Withdrawn | Weill Medical College of Cornell University | Phase 4 | 2021-03-01 | The purpose of this study is to assess the duration of time (in weeks) for improvement in objective dry eye markers for people who are placed on lifitegrast 0.5% (Xiidra®), an FDA-approved therapy for dry eyes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Xiidra
Condition Name
Clinical Trial Locations for Xiidra
Trials by Country
Clinical Trial Progress for Xiidra
Clinical Trial Phase
Clinical Trial Sponsors for Xiidra
Sponsor Name
